Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

Rate of Gleason 7 or higher prostate cancer on repeat biopsy after a diagnosis of atypical small acinar proliferation

Prostate Cancer and Prostatic Diseases volume 18, pages 255–259 (2015)Cite this article

Subjects

Abstract

Background:

Limited information is known about the clinical significance of cancers diagnosed upon repeat biopsy for the indication of atypical small acinar proliferation (ASAP). With increasing concern regarding overdiagnosis and overtreatment of prostate cancer, and the reported rise in infectious complications related to prostate biopsy, we examined the outcomes of patients rebiopsied for a diagnosis of ASAP.

Methods:

Clinical, pathologic and outcomes data of patients diagnosed with ASAP on prostate biopsy at our institutions between 2000 and 2010 were abstracted through chart review. Statistical analyses included Fisher’s exact and the two-sample Wilcoxon rank sum tests. Logistic regression evaluated risk factors for the probability of cancer following a diagnosis of ASAP.

Results:

A total of 349 patients met the inclusion criteria with median follow-up of 4.4 years. Median age was 65.3 years with a median PSA of 5.3 ng ml–1. Of men diagnosed with ASAP, 250/349 (71.6%) had a repeat biopsy within 1 year with 94/246 (38.2%) demonstrating prostate cancer; only 26/245 (10.6%) had ⩾Gleason 7 disease. Of men diagnosed with ASAP, 284/349 (81.4%) underwent biopsy at some time during follow-up. Prostate cancer was diagnosed in 132/279 (47.3%) of these men, 48/278 (17.3%) with ⩾Gleason 7 disease. Multivariate analyses suggested that older age, no previous biopsy and PSA density were predictive of cancer on repeat biopsy within 1 year from ASAP. Univariate analysis revealed PSA density was associated with the presence of ⩾Gleason 7 disease at 1 year and any time after a diagnosis of ASAP.

Conclusions:

The overall rate of intermediate- and high-grade prostate cancer found on repeat biopsy for ASAP is low. Further investigation into ways to further risk stratify these men may be warranted. However, until such tests become available, repeat biopsy of men diagnosed with ASAP remains prudent.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A . Cancer statistics. 2013 CA Cancer J Clin 2013; 63: 11–30.

    Article  PubMed  Google Scholar 

  2. Andriole GL, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310–1319.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Schroder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V et al. Screening and prostate-cancer mortality in a randomized european study. N Engl J Med 2009; 360: 1320–1328.

    Article  PubMed  Google Scholar 

  4. Mosharafa AA, Torky MH, El Said WM, Meshref A . Rising incidence of acute prostatitis following prostate biopsy: fluoroquinolone resistance and exposure is a significant risk factor. Urology 2011; 78: 511–514.

    Article  PubMed  Google Scholar 

  5. Zaytoun OM, Vargo EH, Rajan R, Berglund R, Gordon S, Jones JS . Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology 2011; 77: 1035–1041.

    Article  PubMed  Google Scholar 

  6. Iczkowski KA, Bassler TJ, Schwob VS, Bassler IC, Kunnel BS, Orozco RE et al. Diagnosis of “suspicious for malignancy” in prostate biopsies: predictive value for cancer. Urology 1998; 51: 749–757; discussion 57–58.

    Article  CAS  PubMed  Google Scholar 

  7. Ouyang RC, Kenwright DN, Nacey JN, Delahunt B . The presence of atypical small acinar proliferation in prostate needle biopsy is predictive of carcinoma on subsequent biopsy. BJU Int 2001; 87: 70–74.

    Article  CAS  PubMed  Google Scholar 

  8. Epstein JI, Herawi M . Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 2006; 175: 820–834.

    Article  PubMed  Google Scholar 

  9. Moyer VA . Force USPST. Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2012; 157: 120–134.

    Article  PubMed  Google Scholar 

  10. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL et al. Early detection of prostate cancer: AUA guideline. J Urol 2013; 190: 419–426.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Ehdaie B, Vertosick E, Spaliviero M, Giallo-Uvino A, Taur Y, O'Sullivan M et al. The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance. J Urol 2014; 191: 660–664.

    Article  PubMed  Google Scholar 

  12. Hoedemaeker RF, Kranse R, Rietbergen JB, Kruger AE, Schroder FH, van der Kwast TH . Evaluation of prostate needle biopsies in a population-based screening study: the impact of borderline lesions. Cancer 1999; 85: 145–152.

    Article  CAS  PubMed  Google Scholar 

  13. Chan TY, Epstein JI . Follow-up of atypical prostate needle biopsies suspicious for cancer. Urology 1999; 53: 351–355.

    Article  CAS  PubMed  Google Scholar 

  14. Chen YB, Pierorazio PM, Epstein JI . Initial atypical diagnosis with carcinoma on subsequent prostate needle biopsy: findings at radical prostatectomy. J Urol 2010; 184: 1953–1957.

    Article  PubMed  Google Scholar 

  15. Pinto PA, Chung PH, Rastinehad AR, Baccala AA Jr ., Kruecker J, Benjamin CJ et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol 2011; 186: 1281–1285.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Vourganti S, Rastinehad A, Yerram NK, Nix J, Volkin D, Hoang A et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol 2012; 188: 2152–2157.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Minnesota, Minneapolis, MN, USA

    C Warlick, J Tomasini & M Risk

  2. Division of Urology, Department of Surgery, Hennepin County Medical Center, Minneapolis, MN, USA

    K Feia

  3. Department of Pathology, Department of Veterans Affairs Hospital, Minneapolis, MN, USA

    C Iwamoto & M Risk

  4. Masonic Cancer Center, Biostatistics and Bioinformatics Core, University of Minnesota, Minneapolis, MN, USA

    B Lindgren

Authors
  1. C Warlick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Feia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Tomasini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Iwamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Lindgren
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Risk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Warlick.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Warlick, C., Feia, K., Tomasini, J. et al. Rate of Gleason 7 or higher prostate cancer on repeat biopsy after a diagnosis of atypical small acinar proliferation. Prostate Cancer Prostatic Dis 18, 255–259 (2015). https://doi.org/10.1038/pcan.2015.14

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2015.14

This article is cited by

Search

Advanced search

Quick links